Table 5 Adjusted odds ratios (OR) and 95% confidence intervals (CI) of the presence of hyperuricemia associated with the visceral adiposity index, along with metabolic health and obesity phenotypes stratified by age groups.

From: Visceral adiposity index is strongly associated with hyperuricemia independently of metabolic health and obesity phenotypes

 

ATP-III criteria

HOMA criteria

Below 65 years

Above 65 years

Below 65 years

Above 65 years

Visceral adiposity index

1st Quartile

1 (Ref)

1 (Ref)

1 (Ref)

1 (Ref)

2nd Quartile

1.36 (1.07–1.73)

1.09 (0.74–1.62)

1.35 (1.07–1.72)

1.1 (0.74–1.63)

3rd Quartile

2.05 (1.62–2.6)

1.07 (0.71–1.62)

2.13 (1.69–2.67)

1.16 (0.78–1.72)

4th Quartile

4.99 (3.84–6.49)

2.78 (1.77–4.39)

5.78 (4.61–7.23)

3.35 (2.25–4.98)

Obesity phenotype

MHNO

1 (Ref)

1 (Ref)

1 (Ref)

1 (Ref)

MUNO

1.29 (1.03–1.61)

1.32 (0.9–1.95)

1.64 (1.31–2.04)

1.24 (0.84–1.85)

MHO

1.1 (0.86–1.41)

1.22 (0.73–2.04)

1.17 (0.97–1.41)

1.21 (0.83–1.77)

MUO

1.71 (1.33–2.18)

2.35 (1.5–3.67)

1.93 (1.53–2.43)

2.71 (1.76–4.18)

  1. Abbreviations: ATP-III, the Adult Treatment P anel-III; HOMA, homeostasis model assessment of insulin resistance; MHNO, metabolically healthy non-obese; MUNO, metabolically unhealthy non-obese; MHO, metabolically healthy obese; and MUO, metabolically unhealthy obese. Model was adjusted for age, sex, urban/rural resident, smoking status, alcohol status, metabolic health-obesity phenotypes, white blood cell, total cholesterol, blood pressure, glucose and hs-CR.
Back to article page